Browsing by Author "Sezgin V.C."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Treatment of Metastatic Breast Cancer with Capecitabine: Efficacy and Toxicity; [Metastatik Meme Kanserinin Tedavisinde Capecitabine: Etkinlik ve Toksisite]
    (2003) Sezgin V.C.; Şanli U.A.; Karabulut B.; Uslu R.; Müezzinoǧlu G.G.; Göker E.; Özdemir N.
    Capecitabine is an oral fluoropyrimidine that mimics continuous infusion 5-fluorouracil. As an oral agent, capecitabine is more convenient for patients and medical oncologists, and avoids the complications associated with venous access. Clinical trials have demonstrated the efficacy and tolerability of capecitabine in anthracycline and taxane pretreated metastatic breast cancer. In this study, we evaluated efficacy and tolerability of capecitabine in anthracycline and taxane pretreated metastatic breast cancer retrospectively. A total of 42 patients received oral capecitabine 2000 mg/m2/daily, on days 1-14 of each 3-week treatment cycle. Complete response not achieved. The partial and stable response rate were %19, %45,2 respectively. Median progression free survival time was 5 months. Additionally, cerbB2 subgroup analysis was performed. Progression free survival was longer in cerbB2 negative group than cerbB2 positive group. Difference between two groups was statistically significant. Oral capecitabine monotherapy demonstrated an acceptable safety profile. There was a low incidence of grade 3-4 adverse event. Capecitabine therapy, has antitumor activity and an acceptable safety profile in this setting.
  • No Thumbnail Available
    Item
    Necrotising myofasiitis after chemotherapy: A case report; [Kemoterapi sonrasinda gelişen nekrotizan miyofasiitis: Olgu sunumu]
    (2004) Karabulut B.; Kirçelli F.; Sezgin V.C.; Müezzinoǧlu G.G.; Şanli U.A.; Uslu R.; Gökmen E.; Göker E.
    Nekrotising myofasciitis (NMF) is a rare infection that involves subcutaneus tissues, especially fascia and the muscular tissues. It can happen on the basis of immunosupression, tumour, surgery and injection which impair tissue integrity in cancer patients. A 37 year old male, diagnosed as nasopharyngeal carcinoma was accepted to the emergency servise 15 days after chemotherapy with pain in his gluteal region, that later turned to a necrotising lesion involving proximal left lower limb, left lower part of the abdomen and distal right lower limb. No etiological factor was found although all microbiological, pathological and rheumatological tests were done. NMF was taken under control with broad spectrum antibiotics and prompt surgical exploration and removal.
  • No Thumbnail Available
    Item
    The efficacy and tolerability of intermediate high dose interferon alpha 2B treatment as an adjuvant therapy of high risk malignant melanoma; [Yüksek riskli malign melanomun adjuvan tedavisinde orta yüksek doz i̇nterferon alfa-2B tedavisinin etkinliǧi ve tolerabilitesi]
    (2005) Karabulut B.; Sezgin V.C.; Göksel G.; Şanli U.A.; Uslu R.; Göker E.
    There are still ongoing clinical trials and debates about adjuvant treatment of malignant melanoma. Between 1995 and 2004, fourty-nine patients with high risk operated non-metastatic malignant melanoma who had been treated with intermediate dose of interferon alpha were enrolled to the study. Twenty-three patients had regional lymph node metastasis at the time of diagnosis. Patients were treated with interferon alpha 2b (10 million units/day, five times a week for four weeks) as an induction therapy, followed by interferon alpha 2b (10 million units/day interferon three times a week for eleven months) as a maintanence therapy. The median follow-up time was 35 months (range 2-101 months). In this period, 7(14%) of patients had local recurrence, 12 (24%) of patients had regional lymph node metastasis and 20 (41%) of patients had distant metastasis. The 5-years overall survival, disease free survival and distant metastasis free survival rate of patients were 68%, 32% and 54% respectively. Therapy was well tolerated, no grade 4 toxicity related to therapy was observed. Comparing to natural history of malignant melanoma, these results are found to be encouraged.